EnginZyme raises SEK 75m for commercial biomanufacturing
Lotus One Investment, Valquest Partners Europe and existing backers participated as EnginZyme shifts toward commercial deployment.
EnginZyme raised SEK 75 million, approximately $7.6 million, to support the move from research and development toward commercial biomanufacturing. Participants included Lotus One Investment, Valquest Partners Europe, Sofinnova Partners, Industrifonden, Navigare Ventures and Almi Invest GreenTech.
The financing supports work with manufacturers in personal care, food and pharmaceuticals. EnginZyme develops enzyme-based production processes, taking industrial partners from feasibility analysis through manufacturing scale-up.
Use of funds
Move enzyme-based manufacturing from R&D toward commercially driven biomanufacturing in personal care, food and pharmaceuticals.